×
Join our live online event
How top hedge funds use news to make money
form the stock market & how ordinary people are
copying their strategies
Register now!
form the stock market & how ordinary people are
copying their strategies
No thanks
TENX – tenax therapeutics, inc. (US:NASDAQ)
DELAYED
$
| Volume Shares | |
| 1 Day Range | |
| Volume Ratio | |
| 52 Week High | |
| 52 Week Low |
| VWAP | |
| Today’s Volatility | |
| 20 Days Volatility | |
| Open | |
| Prior Close |
1D
5D
1M
3M
YTD
1Y
3Y
1 Day
TENX
SPY
QQQ
Swipe to see more
Main News & Impact Reports
Date
Time
Symbol
Headline
Impact
3/17
08:43 am
tenx
Tenax Therapeutics (TENX) is now covered by Cantor Fitzgerald. They set an "overweight" rating and a $35.00 price target on the stock.
Medium
Report
Tenax Therapeutics (TENX) is now covered by Cantor Fitzgerald. They set an "overweight" rating and a $35.00 price target on the stock.
3/16
09:16 am
tenx
Tenax Therapeutics (TENX) had its price target raised by Guggenheim from $25.00 to $34.00. They now have a "buy" rating on the stock.
Medium
Report
Tenax Therapeutics (TENX) had its price target raised by Guggenheim from $25.00 to $34.00. They now have a "buy" rating on the stock.
3/13
06:18 am
tenx
Tenax Therapeutics (TENX) was upgraded by Lifesci Capital to "strong-buy".
Low
Report
Tenax Therapeutics (TENX) was upgraded by Lifesci Capital to "strong-buy".
3/10
05:04 pm
tenx
Tenax Therapeutics (TENX) had its "outperform" rating reaffirmed by William Blair.
Low
Report
Tenax Therapeutics (TENX) had its "outperform" rating reaffirmed by William Blair.
3/10
07:30 am
tenx
Tenax Therapeutics GAAP EPS of -$0.38 beats by $0.03 [Seeking Alpha]
High
Report
Tenax Therapeutics GAAP EPS of -$0.38 beats by $0.03 [Seeking Alpha]
3/10
07:08 am
tenx
Tenax Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Corporate Update [Yahoo! Finance]
High
Report
Tenax Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Corporate Update [Yahoo! Finance]
3/10
07:00 am
tenx
Tenax Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Corporate Update
High
Report
Tenax Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Corporate Update
3/3
07:29 am
tenx
Tenax Therapeutics to Participate in the 2026 Leerink Partners Global Healthcare Conference [Yahoo! Finance]
Medium
Report
Tenax Therapeutics to Participate in the 2026 Leerink Partners Global Healthcare Conference [Yahoo! Finance]
Date
Time
Symbol
Company Name
Action
%Chg
Date
Time
Action
From
To
Firm
Impact
%Chg
Date
Time
Symbol
Headline
Impact
3/10
06:03 pm
tenx
Form SCHEDULE 13D TENAX THERAPEUTICS, INC. Filed by: Giordano Christopher Thomas
Medium
Report
Form SCHEDULE 13D TENAX THERAPEUTICS, INC. Filed by: Giordano Christopher Thomas
3/10
07:49 am
tenx
Form 10-K TENAX THERAPEUTICS, INC. For: Dec 31
High
Report
Form 10-K TENAX THERAPEUTICS, INC. For: Dec 31
3/10
07:33 am
tenx
Form 8-K TENAX THERAPEUTICS, INC. For: Mar 10
High
Report
Form 8-K TENAX THERAPEUTICS, INC. For: Mar 10
3/9
12:24 pm
tenx
Form SCHEDULE 13G TENAX THERAPEUTICS, INC. Filed by: Logos Global Management LP
Low
Report
Form SCHEDULE 13G TENAX THERAPEUTICS, INC. Filed by: Logos Global Management LP
2/17
06:20 pm
tenx
Form SCHEDULE 13G/A TENAX THERAPEUTICS, INC. Filed by: Venrock Healthcare Capital Partners III, L.P.
Low
Report
Form SCHEDULE 13G/A TENAX THERAPEUTICS, INC. Filed by: Venrock Healthcare Capital Partners III, L.P.
2/17
04:28 pm
tenx
Form SCHEDULE 13G/A TENAX THERAPEUTICS, INC. Filed by: Point72 Asset Management, L.P.
Low
Report
Form SCHEDULE 13G/A TENAX THERAPEUTICS, INC. Filed by: Point72 Asset Management, L.P.
2/17
04:28 pm
tenx
Form SCHEDULE 13G/A TENAX THERAPEUTICS, INC. Filed by: BIOTECHNOLOGY VALUE FUND L P
Low
Report
Form SCHEDULE 13G/A TENAX THERAPEUTICS, INC. Filed by: BIOTECHNOLOGY VALUE FUND L P
2/17
04:09 pm
tenx
Form SCHEDULE 13G/A TENAX THERAPEUTICS, INC. Filed by: Lind Global Fund II LP
Low
Report
Form SCHEDULE 13G/A TENAX THERAPEUTICS, INC. Filed by: Lind Global Fund II LP
Stock Stats
| News Stats | |
|---|---|
| All News | |
| News Wires | |
| Media Monitoring | |
| SEC Edgar Filings | |
| Upgrades | |
| Downgrades | |
| Initiated | |
| Reiterated | |
| Last Earnings | |
| Last Earnings EPS | |
| Next Earnings | |
| Order Stats |
|---|
| Sub-Penny |
|
|
| Odd lot |
|
|
| Avg. bid-ask spread |
|
|
| Avg. bid-ask size |
|
|
| Shares at ask/bid |
|
|
| Off exchange |
|
|
Main News & Impact Reports
TOP News Gainers
10/31
Tenax Therapeutics Provides Update on Phase 2 Pulmonary Hypertension Clinical Trial
7.4%
1/15 Tenax Therapeutics Inc (NASDAQ: TENX) was upgraded by analysts at ValuEngine from a "hold" rating to a "buy" rating. 4.8%
6/14 Form 8-K TENAX THERAPEUTICS, INC. For: Jun 13 4.7%
1/22 Tenax Therapeutics Inc (NASDAQ: TENX) was downgraded by analysts at ValuEngine from a "buy" rating to a "hold" rating. 4.3%
8/23 Tenax Therapeutics Provides Clinical Development Update 3.4%
8/30 Form S-8 TENAX THERAPEUTICS, INC. 2.5%
11/8 Form 8-K/A TENAX THERAPEUTICS, INC. For: Jun 13 2.5%
4/29 Form 8-K TENAX THERAPEUTICS, INC. For: Apr 24 2.3%
3/30 Form 10-K TENAX THERAPEUTICS, INC. For: Dec 31 2.1%
2/14 Form SC 13G/A TENAX THERAPEUTICS, INC. Filed by: Iroquois Capital Management, LLC 0.0%
1/15 Tenax Therapeutics Inc (NASDAQ: TENX) was upgraded by analysts at ValuEngine from a "hold" rating to a "buy" rating. 4.8%
6/14 Form 8-K TENAX THERAPEUTICS, INC. For: Jun 13 4.7%
1/22 Tenax Therapeutics Inc (NASDAQ: TENX) was downgraded by analysts at ValuEngine from a "buy" rating to a "hold" rating. 4.3%
8/23 Tenax Therapeutics Provides Clinical Development Update 3.4%
8/30 Form S-8 TENAX THERAPEUTICS, INC. 2.5%
11/8 Form 8-K/A TENAX THERAPEUTICS, INC. For: Jun 13 2.5%
4/29 Form 8-K TENAX THERAPEUTICS, INC. For: Apr 24 2.3%
3/30 Form 10-K TENAX THERAPEUTICS, INC. For: Dec 31 2.1%
2/14 Form SC 13G/A TENAX THERAPEUTICS, INC. Filed by: Iroquois Capital Management, LLC 0.0%
TOP News Decliners
3/13
Form 8-K TENAX THERAPEUTICS, INC. For: Mar 11
-35.8%
2/29 Tenax Therapeutics Inc (NASDAQ: TENX) was downgraded by analysts at ValuEngine from a "buy" rating to a "hold" rating. -10.8%
1/13 Form 8-K TENAX THERAPEUTICS, INC. For: Jan 13 -7.9%
4/9 Tenax Therapeutics Announces Last Patient Completes Final Visit in its Phase 2 “HELP Study” of Levosimendan for Pulmonary Hypertension and Heart Failure with Preserved Ejection Fraction -6.7%
2/21 Tenax Announces the Addition of Mayo Clinic Expert, Dr. Barry Borlaug, to Scientific Advisory Board -5.8%
2/7 Form SC 13G TENAX THERAPEUTICS, INC. Filed by: BlackRock Inc. -5.7%
3/27 Form D TENAX THERAPEUTICS, INC. -5.6%
5/15 Q1/2019 3/31/2019 EPS -0.330 ZacksConsensus N/A ActVsEst N/A - N/A -4.2%
8/14 Q2/2019 6/30/2019 EPS -0.280 ZacksConsensus -0.450 ActVsEst 0.170 - Beat -4.2%
3/23 Form SC 13G TENAX THERAPEUTICS, INC. Filed by: ARMISTICE CAPITAL, LLC -2.0%
2/29 Tenax Therapeutics Inc (NASDAQ: TENX) was downgraded by analysts at ValuEngine from a "buy" rating to a "hold" rating. -10.8%
1/13 Form 8-K TENAX THERAPEUTICS, INC. For: Jan 13 -7.9%
4/9 Tenax Therapeutics Announces Last Patient Completes Final Visit in its Phase 2 “HELP Study” of Levosimendan for Pulmonary Hypertension and Heart Failure with Preserved Ejection Fraction -6.7%
2/21 Tenax Announces the Addition of Mayo Clinic Expert, Dr. Barry Borlaug, to Scientific Advisory Board -5.8%
2/7 Form SC 13G TENAX THERAPEUTICS, INC. Filed by: BlackRock Inc. -5.7%
3/27 Form D TENAX THERAPEUTICS, INC. -5.6%
5/15 Q1/2019 3/31/2019 EPS -0.330 ZacksConsensus N/A ActVsEst N/A - N/A -4.2%
8/14 Q2/2019 6/30/2019 EPS -0.280 ZacksConsensus -0.450 ActVsEst 0.170 - Beat -4.2%
3/23 Form SC 13G TENAX THERAPEUTICS, INC. Filed by: ARMISTICE CAPITAL, LLC -2.0%
Don’t Miss Out On The Next BIG Stock Move
Never get left behind with our daily ‘Shakers & Movers’ newsletter. Discover the biggest gainer or loser in the stock market, and learn exactly WHY it moved. To find out which one caught Wall Street by surprise TODAY, sign up to our newsletter below: